Rose bengal

Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium

Retrieved on: 
Mercoledì, Marzo 27, 2024
Opacity (optics), Risk, Patient, RBS, University, PDAT, Bascom Palmer Eye Institute, Rose bengal, Eye, Infection, Keratitis, Safety, Paratriathlon, Ophthalmology, OBC, Pharmaceutical industry

Provectus would contribute the license to the new entity and have an exclusive RBS supply arrangement with it.

Key Points: 
  • Provectus would contribute the license to the new entity and have an exclusive RBS supply arrangement with it.
  • Rose bengal PDAT emerged under the leadership of Jean-Marie Parel, IngETS-G, Ph.D., FARVO, Director of the Ophthalmic Biophysics Center (“OBC”) at Bascom Palmer Eye Institute (“BPEI”) at the University of Miami Miller School of Medicine.
  • The OBC team and Dr. Parel have spent many years advancing their PDAT technology using rose bengal against different types of treatment-naïve and -resistant keratitis.
  • Dr. Parel said, “Rose bengal PDAT is the result of a lot of hard work by cross-disciplinary contributors at the University of Miami.

Global Dry Eye Treatment Devices Market Report 2022: An Upsurge in The Number of Eye Care Facilities Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Novembre 14, 2022
Health, Optical, Patient, Stinger, Prevalence, Fluorescein, Thyroid, Ophthalmology, Visual impairment, Tears, Hyperaemia, Rheumatoid arthritis, Lupus, DED, Dry eye syndrome, Tearing, Dry, Conditional sentence, Maintenance, Green, Eye, Grit, Wound healing, Diabetes, Schirmer, Rose bengal, Infection, Blepharitis, Drainage, Sjögren syndrome, Cosmetics

The "Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report by Technology, End-user, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report by Technology, End-user, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Dry Eye Treatment Devices Market size is expected to reach $348.8 million by 2028, rising at a market growth of 7.4% CAGR during the forecast period.
  • Several medical remedies and methods are either on the market or being researched for the management of DED.
  • The number of people with dry eyes has grown recently for a variety of causes, leading to an increase in eye care facilities.

Provectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections

Retrieved on: 
Mercoledì, Settembre 21, 2022
IL, National, HX-21, Safety, Fungal keratitis, Lasers in Medical Science, Legislation, Bascom, Hematology, Physician, Percussion section, NIH, HX, Time, U.S. News & World Report, Glaucoma, Neuro-ophthalmology, Company, Riboflavin, UM, Degenerative disease, No, Cornea, Staphylococcus, Adriana Arboleda, Doctor of Philosophy, SEC, Veni, vidi, vici, Methicillin-resistant Staphylococcus aureus, PDAT, Retina, University, Review, MD, OTCQB, Health, Surgical Outcomes Analysis and Research, Forward-looking statement, Severe cognitive impairment, Pseudomonas aeruginosa, Patient, GLOBE, Drug discovery, Department, OBC, Immunotherapy, Cataract, Dermatology, Eye, P.O, Quality of life, Bascom Palmer Eye Institute, Laser, Rose bengal, Infection, Staphylococcus aureus, Pharmaceutical industry, Antibiotics, Copper, Ophthalmology, U.S

The Company also initiated a sponsored research program with OBC to investigate Provectus rose bengal for the treatment of infectious keratitis.

Key Points: 
  • The Company also initiated a sponsored research program with OBC to investigate Provectus rose bengal for the treatment of infectious keratitis.
  • BPEI serves as the Department of Ophthalmology for the UM Miller School of Medicine in Miami, Florida.
  • Its mission is to enhance the quality of life by improving sight, preventing blindness, and advancing ophthalmic knowledge through compassionate patient care and innovative research.
  • 1 ranking since U.S. News began surveying American physicians for its annual Best Hospitals rankings 33 years ago.

Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions

Retrieved on: 
Mercoledì, Marzo 31, 2021
Organic compounds, Aromatic compounds, Chemical compounds, Cancer, Melanoma, Chloroarenes, Rose bengal

The Melanoma Research article, entitled Treatment of in-transit melanoma metastases using intralesional PV-10, detailed the experience of investigators at Melanoma Institute Australia (MIA; formerly the Sydney Melanoma Unit) in Sydney, Australia who treated 48 patients from 2008 to 2016.

Key Points: 
  • The Melanoma Research article, entitled Treatment of in-transit melanoma metastases using intralesional PV-10, detailed the experience of investigators at Melanoma Institute Australia (MIA; formerly the Sydney Melanoma Unit) in Sydney, Australia who treated 48 patients from 2008 to 2016.
  • This is the third publication about single-agent PV-10 treatment of ITM lesions under Provectus EAP (which has treated about 200 patients to date) and the fifth publication overall.
  • Mel Res 2008 ; subscription required): 11 (out of 20) patients treated in the Phase 1 trial; 1 PV-10 treatment; 27% patient CR (54% ORR).
  • Cancer Council Australia, Clinical practice guidelines for the diagnosis and management of melanoma: Treatment of satellite and in-transit metastases (May 2018)

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020

Retrieved on: 
Giovedì, Novembre 12, 2020
Life sciences, Organic compounds, Health sciences, Biotechnology, Cancer immunotherapy, Chloroarenes, Phenols, Rose bengal, Immunotherapy, Biopharmaceutical, Melanoma

A first expansion cohort of the Phase 1b portion of the study began enrolling patients with metastatic cutaneous melanoma who were CB-refractory in December 2018.

Key Points: 
  • A first expansion cohort of the Phase 1b portion of the study began enrolling patients with metastatic cutaneous melanoma who were CB-refractory in December 2018.
  • The protocol allows for additional cycles of PV-10 beyond the fifth cycle for patients with additional injectable disease.
  • Provectus' RBD and cGMP RBD manufacturing process are protected by composition of matter and manufacturing patents as well as trade secrets.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on an entirely- and wholly-owned family of small molecules called halogenated xanthenes.

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee Health Science Center to Investigate Small Molecule Rose Bengal Disodium for Antibiotic Resistance

Retrieved on: 
Mercoledì, Settembre 9, 2020
Organic compounds, Aromatic compounds, Chemical compounds, Chloroarenes, Ophthalmology, Phenols, Rose bengal, RBD, CGMP

RBD is Provectus proprietary lead molecule, and a member of a class of small molecules called halogenated xanthenes that is entirely and wholly owned by the Company.

Key Points: 
  • RBD is Provectus proprietary lead molecule, and a member of a class of small molecules called halogenated xanthenes that is entirely and wholly owned by the Company.
  • Provectus RBD and cGMP RBD manufacturing process are protected by composition of matter and manufacturing patents as well as trade secrets.
  • Such work is fundamental to the continued expansion of Provectus drug product platform, where disease-specific formulations of rose bengal disodium can be delivered by oral, intralesional, topical, and potentially other routes of administration.
  • RBD is 4,5,6,7-tetrachloro-2,4,5,7-tetraiodofluorescein disodium, a halogenated xanthene and Provectus proprietary lead molecule.

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Oral Administration of Rose Bengal Disodium for Cancer Treatment

Retrieved on: 
Giovedì, Agosto 13, 2020
Life sciences, Organic compounds, Aromatic compounds, Biotechnology, Pharmaceutical industry, CGMP, Biopharmaceutical, Rose bengal, Pharmaceutical industry in India, Rod cell

The Company's cGMP RBD manufacturing process is protected by composition of matter and manufacturing patents as well as trade secrets.

Key Points: 
  • The Company's cGMP RBD manufacturing process is protected by composition of matter and manufacturing patents as well as trade secrets.
  • Oral administration of a new rose bengal disodium formulation for cancer treatment is a potential novel drug product for Provectus and the logical outgrowth of the Companys expansive medical science platform and strong clinical foundation.
  • cGMP RBD is 4,5,6,7-tetrachloro-2,4,5,7-tetraiodofluorescein disodium, which is a small molecule halogenated xanthene and Provectus proprietary lead compound.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines based on an entirely- and wholly-owned family of chemical small molecules called halogenated xanthenes.

Provectus Biopharmaceuticals Announces Acceptance of Two PV-10® Melanoma Cancer Abstracts at European Society for Medical Oncology (ESMO) Virtual Congress 2020

Retrieved on: 
Mercoledì, Luglio 22, 2020
Organic compounds, Aromatic compounds, Branches of biology, Vesicles, Chloroarenes, Ophthalmology, Phenols, Rose bengal, Lysosome, Pharmaceutics, CGMP

Presentation details will be announced closer to the ESMO Virtual Congress 2020.

Key Points: 
  • Presentation details will be announced closer to the ESMO Virtual Congress 2020.
  • An injectable pharmaceutical product, PV-10 is a proprietary formulation of the Companys current Good Manufacturing Practice (cGMP) rose bengal disodium (RB).
  • The Companys RB manufacturing process is protected by composition of matter and manufacturing patents as well as trade secrets.
  • PV-10 selectively accumulates in the lysosomes of cancer cells upon contact, disrupting the lysosomes and causing the cells to die.

Provectus Announces Presentation of Updated Data from Metastatic Uveal Melanoma Cohort of Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

Retrieved on: 
Lunedì, Giugno 1, 2020
Melanoma, Aromatic compounds, Organic compounds, Medicine, Uveal melanoma, Rose bengal

Response assessments using European Association of the Study of the Liver (2D-EASL) criteria are performed at Day 28, and then every three months.

Key Points: 
  • Response assessments using European Association of the Study of the Liver (2D-EASL) criteria are performed at Day 28, and then every three months.
  • Patients with additional injectable tumors and/or unresponsive injected tumors may receive additional PV-10 after Day 28.
  • This study is now enrolling patients into a single-center cohort at MDACC of up to 25 uveal melanoma patients with hepatic metastases.
  • Eligible patients may also receive standard of care CB during and after treatment with PV-10.